Enanta Pharmaceuticals, Inc. (ENTA)
- Previous Close
13.44 - Open
13.37 - Bid 13.08 x 100
- Ask 13.15 x 100
- Day's Range
13.04 - 13.71 - 52 Week Range
8.08 - 37.75 - Volume
108,198 - Avg. Volume
234,048 - Market Cap (intraday)
278.201M - Beta (5Y Monthly) 0.49
- PE Ratio (TTM)
-- - EPS (TTM)
-6.57 - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
22.29
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
www.enanta.comRecent News: ENTA
Performance Overview: ENTA
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ENTA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ENTA
Valuation Measures
Market Cap
283.91M
Enterprise Value
-27.75M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.83
Price/Book (mrq)
1.48
Enterprise Value/Revenue
-0.38
Enterprise Value/EBITDA
0.22
Financial Highlights
Profitability and Income Statement
Profit Margin
-187.77%
Return on Assets (ttm)
-22.89%
Return on Equity (ttm)
-56.11%
Revenue (ttm)
73.62M
Net Income Avi to Common (ttm)
-138.24M
Diluted EPS (ttm)
-6.57
Balance Sheet and Cash Flow
Total Cash (mrq)
337.15M
Total Debt/Equity (mrq)
112.07%
Levered Free Cash Flow (ttm)
-51.68M
Research Analysis: ENTA
Company Insights: ENTA
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: ENTA
ENTA: Lowering target price to $10.00
ENANTA PHARMACEUTICALS INC has an Investment Rating of SELL; a target price of $10.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetENTA: What does Argus have to say about ENTA?
ENANTA PHARMACEUTICALS INC has an Investment Rating of SELL; a target price of $12.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetENTA: What does Argus have to say about ENTA?
ENANTA PHARMACEUTICALS INC has an Investment Rating of SELL; a target price of $12.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetENTA: Lowering target price to $12.00
ENANTA PHARMACEUTICALS INC has an Investment Rating of SELL; a target price of $12.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice Target